SCLC NewsLatest News On SCLC Zenocutuzumab Effective Against NRG1 Fusion Cancers2/7/2025 8:46 AM Last Month in Oncology: FDA Cancer News Roundup1/7/2025 7:21 AM FDA Approves Durvalumab for Limited-Stage SCLC12/6/2024 1:26 AM Why a Failed Confirmatory Trial May Not Mean a Failed Drug11/8/2024 5:40 AM Should First-Line Dual Checkpoint Blockade Be Used for NSCLC With Specific Mutations?10/24/2024 8:00 AM Gotistobart Trial for NSCLC on Partial Clinical Hold10/23/2024 4:58 AM Can Wearable Devices Support Recovery After Lung Cancer Surgery?10/9/2024 6:43 AM Durvalumab Enhances Survival After Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer10/8/2024 6:26 AM SBRT vs Hypofractionated Radiotherapy for Stage I NSCLC?10/7/2024 9:00 AM Nivolumab NSCLC Approval Expanded to Perioperative Setting10/3/2024 3:13 PM Immunotherapy Should Come After Radiation in SCLC10/3/2024 9:23 AM Minimal Risks With SBRT in Stage I NSCLC9/26/2024 7:26 AM FDA Highlights Concerns Over International Cancer Trials in Draft Guidance9/24/2024 4:04 AM FDA Expands Indication for Amivantamab in Lung Cancer9/23/2024 1:33 AM Europe Recommends Lung Cancer Drug Hetronifly9/20/2024 12:34 PM FDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer Indications9/16/2024 1:52 AM CARMEN-LC03 Fails, but Hope Remains for CEACAM5 Targeting9/12/2024 10:19 AM Novel ADC Shows Promise in Pretreated Extensive SCLC9/11/2024 8:11 AM Aumolertinib Promising Maintenance Therapy in EGFR-Mutated NSCLC9/11/2024 7:16 AM Perioperative Pembrolizumab Continues to Show Benefit in NSCLC9/11/2024 1:32 AM
